Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRANITE-ADJUVANT: Neoantigen Vaccine in Colon Cancer
NCT05456165Phase 2Withdrawn
- Sponsor
- Gritstone bio, Inc.
- Start
- May 2022
- Primary completion
- Sep 2022
- Modality
- Gene Editing, Gene Silencing, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of GRT-C901, GRT-R902 in colon cancer, sponsored by Gritstone bio, Inc.. Planned start May 2022; status: withdrawn.
02
Drugs
GRT-C901GRT-R902
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT05456165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05456165.